NextCure financials
$4.85−4.63%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating income | -$15.1M | -$10.1M | -$9.8M | -$8.9M | -$27.3M | -$11.6M | -$12.5M | -$12.5M | -$16.5M | -$18.3M | -$15.8M | -$15.6M |
| Net income | -$14.9M | -$9.8M | -$9.4M | -$8.6M | -$26.8M | -$11.0M | -$11.6M | -$11.5M | -$15.4M | -$17.1M | -$14.5M | -$14.3M |
| Net margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | $-2.80 | $-1.87 | $-2.37 | $-3.22 | $-11.29 | $-4.70 | $-1.76 | $-4.95 | $-6.61 | $-7.32 | $-6.22 | $-6.12 |
| EBITDA | -$9.7M | -$9.8M | -$9.4M | -$8.4M | -$26.7M | -$11.0M | -$12.5M | -$11.8M | -$15.0M | -$15.8M | -$15.0M | -$14.7M |
| Operating cash flow | -$9.7M | -$13.4M | -$7.6M | -$6.3M | -$22.7M | -$13.0M | -$7.0M | -$11.5M | -$9.8M | -$12.6M | -$10.7M | -$12.8M |
| Free cash flow | -$9.7M | -$13.4M | -$7.6M | -$6.3M | -$22.7M | -$13.0M | -$7.0M | -$11.6M | -$10.1M | -$12.6M | -$10.7M | -$13.1M |
| Diluted shares | 5.3M | 5.2M | 4.0M | 2.7M | 2.4M | 2.3M | 6.6M | 2.3M | 2.3M | 2.3M | 2.3M | 2.3M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $15.3M | $15.2M | $26.0M | $7.3M | $4.9M | $21.8M |
| Short-term investments | $4.8M | $14.6M | $15.8M | $21.8M | $30.4M | $34.0M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $22.6M | $38.0M | $50.2M | $39.6M | $47.7M | $67.1M |
| Total liabilities | $10.5M | $11.3M | $15.2M | $16.0M | $16.0M | $11.3M |
| Shareholders' equity | $12.1M | $26.7M | $34.9M | $23.6M | $29.6M | $55.9M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology